HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murthy, K. Articles by Gagnon, J. H. Search for Related Content PubMed Articles by Murthy, K. Articles by Gagnon, J. H.

Results of Preliminary Clinical Trials of the Positron Emission Mammography System PEM-I: A Dedicated Breast Imaging System Producing Glucose Metabolic Images Using FDG

Montreal Neurological Institute, Medical Physics Unit, and Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada

Early detection of breast cancer is crucial for efficient and effective treatment. We have developed an instrument for positron emission mammography (PEM) called PEM-I that performs high-resolution metabolic imaging of breast cancer. Images of glucose metabolism are obtained after injection of 75 MBq FDG. The PEM detectors are integrated into a conventional mammography system, allowing acquisition of the emission images immediately after the mammogram, without subject repositioning, and accurate coregistration of images from the 2 modalities. In this article, we present the results of the first clinical pilot study with the instrument. Methods: Sixteen subjects (age range, 34–76 y) were studied. All subjects were nondiabetic, nonpregnant, and without a history of cancer. They had recently been found to have suggestive mammography findings or a palpable breast mass and underwent lumpectomy or mastectomy within 2 wk of the study. Results from the PEM study were compared with those from mammography and pathology. A PEM test was classified positive (indicating the presence of cancer) if significant focal uptake was seen in the image or if the counting rate in the breast with suggestive findings was significantly higher than in the contralateral breast. Results: Of the 16 subjects studied, 14 were evaluable. Ten cancerous tumors and 4 benign tumors were confirmed by pathologic examination after complete removal of the tumor. PEM correctly detected the presence of disease in 8 of 10 subjects. Findings were false-negative in 2 instances and false-positive in none, giving the instrument 80% sensitivity, 100% specificity, and 86% accuracy. Conclusion: Our preliminary results suggest that PEM can offer a noninvasive method for the diagnosis of breast cancer. Metabolic images from PEM contain unique information not available from conventional morphologic imaging techniques and aid in expeditiously establishing the diagnosis of cancer. In all subjects, the PEM images were of diagnostic quality, with an imaging time of 2–5 min.

Key Words: PET • FDG • breast cancer • metabolic imaging

Received Jun. 16, 1999; revision accepted Nov. 1, 1999.

For correspondence or reprints contact: Christopher J. Thompson, DSc, Montreal Neurological Institute No. 798, 3801 University St., Montreal, Quebec H3A 2B4 Canada.

Related articles in JNM:

Limited Angle, Limited Approach?

Peter P. van Rijk and Alice J. van Dongen
JNM 2000 41: 1859-1860. [Full Text]  

This article has been cited by other articles:

				E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]

				E. L. Rosen, T. G. Turkington, M. S. Soo, J. A. Baker, and R. E. Coleman Detection of Primary Breast Carcinoma with a Dedicated, Large-Field-of-View FDG PET Mammography Device: Initial Experience Radiology, February 1, 2005; 234(2): 527 - 534. [Abstract] [Full Text] [PDF]

				P. P. van Rijk and A. J. van Dongen Limited Angle, Limited Approach? J. Nucl. Med., November 1, 2000; 41(11): 1859 - 1860. [Full Text] [PDF]